What is the half-life of Zilucoplan?

Zilucoplan has an approximate elimination half-life of 7.2 d.

How long does Zilucoplan stay in your system?

Roughly 97% of a dose has cleared after five half-lives — about ~5 weeks for Zilucoplan. That is the window that matters for washouts, bloodwork and surgery.

What are the risks of Zilucoplan?

Boxed warning: serious, life-threatening meningococcal infections; available only through a restricted program (REMS) Other serious Neisseria infections have been reported with complement inhibitors Pancreatitis and pancreatic cysts have been reported

Zilucoplan

Zilbrysq

A synthetic 15-amino-acid macrocyclic peptide complement inhibitor. Approved in the US for generalized myasthenia gravis in adults who are anti-AChR antibody positive.

Half-life: 7.2 d
Out of system: ~5 weeks
Route: Subcutaneous
Level: —

Class (Complement inhibitor), half-life and route from the FDA label: Zilbrysq (zilucoplan) injection (U.S. National Library of Medicine, DailyMed), checked 2026-09-26.

What Zilucoplan is used for

Treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive (FDA label)

How it's typically used

Prescription medicine in the US, under a REMS program with required vaccination. The prescriber sets the dose; the FDA label is cited on this page.

What to watch for

Boxed warning: serious, life-threatening meningococcal infections; available only through a restricted program (REMS)
Other serious Neisseria infections have been reported with complement inhibitors
Pancreatitis and pancreatic cysts have been reported

Common questions

What is the half-life of Zilucoplan?: Zilucoplan has an approximate elimination half-life of 7.2 d.
How long does Zilucoplan stay in your system?: Roughly 97% of a dose has cleared after five half-lives — about ~5 weeks for Zilucoplan. That is the window that matters for washouts, bloodwork and surgery.
How is Zilucoplan taken?: Zilucoplan is typically administered by the subcutaneous route. Prescription medicine in the US, under a REMS program with required vaccination. The prescriber sets the dose; the FDA label is cited on this page.
What are the risks of Zilucoplan?: Boxed warning: serious, life-threatening meningococcal infections; available only through a restricted program (REMS) Other serious Neisseria infections have been reported with complement inhibitors Pancreatitis and pancreatic cysts have been reported

About Other research compounds

What they are: Nootropics, metabolic agents, and research compounds that don't fit the other classes.
How they're run: Route and schedule vary widely — check the individual entry.
What to watch: This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.

Other other research compounds

Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.